Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. FDA approves Gilead’s $94,500 hepatitis C drug

[Reuters] – The daily pill, to be sold under the brand name Harvoni, combines Gilead’s $84,000 pill Sovaldi with another drug, ledipasvir, and eliminates the need for two older, side-effect-laden treatments that needed . . . → Read More: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. FDA approves Gilead’s $94,500 hepatitis C drug Similar Articles: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – England agrees funding for Gilead hepatitis C drug Company Update (NASDAQ:GILD): Texas Medicaid holds off on proposed limits for Gilead hepatitis drug